英文互译镜像站

EQL-101

Last updated
EQL-101
Clinical data
Other namesEQL101
Drug class Non-hallucinogenic and non-cardiotoxic ibogaine analogue

EQL-101 is a non-hallucinogenic ibogaine analogue which is under development for the treatment of substance use disorders such as opioid use disorder. [1] [2] [3] [4] [5] It is said to preserve the therapeutic activity of ibogaine but to lack its hallucinogenic effects as well as certain adverse effects like cardiotoxicity. [1] [3] [4] The drug is under development by Equulus Therapeutics. [1] [2] [3] [4] [5] As of 2025, it is in the discovery or preclinical research stage of development. [5]

Contents

See also

References

  1. 1 2 3 Shah-Neville, Willow (17 April 2024). "Small but mighty: The role of small-molecule drugs in disease treatment". Labiotech.eu. Retrieved 26 January 2026. For example, Discordia's own company, EQUULUS, is developing small-molecule drugs for psychiatric and neurological disorders with a strong focus on addiction disorders. The company's lead asset, EQL-101, is a psychedelic-inspired anti-addiction therapeutic that is based on the therapeutic benefits of ibogaine. This is a naturally-occurring substance from the Iboga tree that has been used for many years to treat substance use disorders but has a significant and long hallucinogenic phase with dangerous and potentially lethal cardiac side effects. "EQL-101 is non-hallucinogenic and non-cardiotoxic but has been shown in preclinical testing to hold similar efficacy to treat addictions to various substances," said Discordia.
  2. 1 2 Psychedelic Alpha (25 April 2024). "Pα+ Psychedelic Bulletin #162: EQUULUS Therapeutics Emerges from Stealth; Responses to ICER's Draft Evidence Report on Lykos' MDMA; and more…". Psychedelic Alpha. Retrieved 26 January 2026.
  3. 1 2 3 Roberts, Madison (10 October 2025). "After the Billion-Dollar Psychedelic Bet: Who's Next for Big Pharma?". Microdose. Retrieved 26 January 2026. A non-hallucinogenic ibogaine analog (EQL-101) — targeting addiction and depression with ibogaine's regenerative neurochemistry but none of its cardiac risk.
  4. 1 2 3 Roberts, Madison (6 May 2024). "Innovating CNS Disorder Treatment: EQUULUS and the Revolutionary Approach with Analog Ibogaine". Microdose. Retrieved 26 January 2026.
  5. 1 2 3 "Psychedelics Drug Development Tracker". Psychedelic Alpha. Retrieved 26 January 2026.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.
镜像网站程序 整站镜像下载 站点核心词加权 百变TDK镜像 伪原创镜像站